免疫抑制药物治疗能否改善系统性硬化症患者的胃肠道症状
该研究纳入209例系统性硬化症(SSc)患者,分析免疫抑制治疗与随访时胃肠道症状严重程度(GIT评分)的关联。多变量线性回归显示,观察期使用免疫抑制治疗及较低基线GIT评分与随访时较低(较好)的GIT评分显著相关。作者认为免疫抑制治疗可能对SSc胃肠道表现有潜在作用,需在前瞻性随机临床试验中确认。
要点
- 观察期使用免疫抑制治疗与随访时较低的GIT评分显著相关。
- 基线GIT评分较低也与随访时较低的GIT评分显著相关。
- 作者认为该关联提示免疫抑制剂对SSc胃肠道表现的潜在作用,需前瞻性随机临床试验确认。
核心结论
- 免疫抑制治疗与本研究队列中较低的GIT评分相关,提示免疫抑制剂对SSc患者胃肠道表现可能有潜在作用,需在前瞻性随机临床试验中确认。
研究设计与样本
- 选取至少两次就诊(基线及随访)且完成GIT问卷、间隔12±3个月的系统性硬化症患者,共纳入209例。
- 采用多变量线性回归分析,协变量包括观察期免疫抑制治疗、基线前免疫抑制治疗、基线GIT评分及经临床判断可能影响胃肠道症状的若干基线参数。
主要发现
- 共纳入209例SSc患者,女性占82.3%,中位年龄59.0岁,中位病程6.0年,弥漫性皮肤型SSc 40例(19.1%),中位基线GIT评分0.19。
- 观察期有71例接受免疫抑制治疗,与未暴露患者相比,其整体SSc病情更重且质子泵抑制剂治疗比例更高。
- 多变量线性回归中,观察期免疫抑制治疗和较低基线GIT评分与随访时较低(较好)的GIT评分显著相关。
局限性
- 作者指出该关联需在前瞻性随机临床试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: While important progress was made regarding the treatment of systemic sclerosis (SSc), there is still no evidence-based disease-modifying treatment available for SSc-related gastrointestinal (GI) manifestations. We aimed to identify an association between immunosuppressive therapy and the the severity of GI symptoms, measured by the University of California at Los Angeles/Scleroderma Clinical Trial Consortium Gastro-Intestinal Tract instrument 2.0 (GIT). METHODS: We selected patients with SSc who had at least two visits (further referred to as 'baseline' and 'follow-up') with completed GITs, within an interval of 12±3 months. The study outcome was the GIT score at follow-up. We used multivariable linear regression with the following covariates: immunosuppressive therapy during observation, immunosuppressive therapy before baseline, baseline GIT and several baseline parameters selected by clinical judgement as potentially influencing GI symptoms. RESULTS: We included 209 SSc patients (82.3% female, median age 59.0 years, median disease duration 6.0 years, 40 (19.1%) diffuse cutaneous SSc, median baseline GIT 0.19). Of these, 71 were exposed to immunosuppressive therapy during the observation period, and, compared with unexposed patients, had overall more severe SSc and a higher prevalence of treatment with proton pump inhibitors. In multivariable linear regression, immunosuppressive therapy during the period of observation and lower baseline GIT scores were significantly associated with lower (better) GIT scores at follow-up. CONCLUSION: Immunosuppressive treatment was associated with lower GIT scores in our cohort, which suggests the potential effects of immunosuppressants on GI manifestations in patients with SSc, requiring confirmation in prospective randomised clinical trials.
引用
- Stamm L, Garaiman A, Becker MO, et al. Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis? RMD Open. 2024. PMID: 39053950. doi:10.1136/rmdopen-2024-004333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。